You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIMC-11F8
Accession NumberDB05774
TypeSmall Molecule
GroupsInvestigational
DescriptionIMC-11F8 is a fully human IgG1 monoclonal antibody that blocks the ligand binding site of EGFR that is involved in triggering and regulating the malignant growth of many EGFR-expressing epithelial tumors. IMC-11F8 is developed for the treatment of advanced colorectal cancer.
Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIINot Available
CAS numberNot Available
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationInvestigated for use/treatment in colorectal cancer.
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionIMC-11F8 is a fully human monoclonal antibody that is designed to bind to the EGFR, thereby inhibiting certain ligands known as growth factors from binding to and activating the receptor. This action blocks a signal pathway key to tumor growth and repair and has also been shown to induce cell death, or apoptosis, in human tumors in animal models.
TargetKindPharmacological actionActionsOrganismUniProt ID
Epidermal growth factor receptorProteinunknownNot AvailableHumanP00533 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with IMC-11F8.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with IMC-11F8.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with IMC-11F8.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with IMC-11F8.Investigational
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with IMC-11F8.Approved
RindopepimutThe therapeutic efficacy of CDX-110 can be decreased when used in combination with IMC-11F8.Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with IMC-11F8.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with IMC-11F8.Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Zhu Z: A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem. 2005 May 20;280(20):19665-72. Epub 2005 Mar 9. [PubMed:15757893 ]
External LinksNot Available
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableTumors, Solid1
1CompletedTreatmentAdvanced Solid Tumors / Neoplasms1
1RecruitingTreatmentEGFR Activating Mutation / Recurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer1
1, 2Active Not RecruitingTreatmentSquamous Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentSquamous Non Small Cell Lung Cancer1
2CompletedTreatmentMalignant Solid Tumors1
2CompletedTreatmentMetastatic Colorectal Cancers1
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentTumors, Solid1
2RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)2
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Ubiquitin protein ligase binding
Specific Function:
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on ke...
Gene Name:
EGFR
Uniprot ID:
P00533
Molecular Weight:
134276.185 Da
Comments
comments powered by Disqus
Drug created on November 18, 2007 11:27 / Updated on August 17, 2016 12:24